Israeli Health-Tech Startup UltraSight Secures $24 Million in Series B2 Funding
Israeli health-tech startup UltraSight has raised $24 million in a Series B2 funding round led by Alive HealthTech Growth Fund, bringing its total capital raised to $42 million.
The Israeli health-tech startup UltraSight, based in Rehovot and specializing in AI-driven cardiac imaging workflows, announced on Wednesday the completion of a $24 million Series B2 funding round.
The investment round was led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures, alongside existing investors including Mayo Clinic Ventures, NYU, and Iron Nation. This latest injection brings the total capital raised by the company since its inception to $42 million.
The newly secured funds will be utilized by UltraSight to expand its commercial operations and deployment across healthcare systems in the United States. Furthermore, the capital will support the ongoing development of novel clinical applications for intensive care units, where rapid access to cardiac imaging has a direct and critical impact on therapeutic decision-making.
Founded in 2018, UltraSight was established by Itay Azourar (CTO), Yaron Lipman (scientific advisor), and Achi Ludomirsky (Chief Medical Officer). The company is led by CEO Davidi Vortman and currently employs 25 people, with 19 based in Israel and the remainder in the United States.
The company operates within the echocardiography market, which is experiencing a significant turning point driven by a continuous surge in demand for cardiac examinations alongside a persistent shortage of skilled professionals, namely sonographers. This imbalance creates bottlenecks, heavy workloads, and delays in clinical decision-making. The company’s flagship platform, the UltraSight Echosystem, is designed to directly address this challenge.
AI-Powered Guidance for Point-of-Care Diagnostics
By integrating structured training and real-time AI-based guidance, the system enables appropriately trained medical staff—even those who are not expert sonographers—to perform targeted point-of-care ultrasound (POCUS) examinations under the supervision of a qualified physician.
This approach enables hospitals to improve patient flow, shorten waiting times, and optimize the utilization of medical personnel. The company's technology rests on a robust clinical foundation, including FDA clearances (510(k)) and clinical studies recently published in leading journals such as JAMA Cardiology, which demonstrate the system's high accuracy in identifying various clinical conditions.
Currently, the UltraSight Echosystem is deployed across more than 10 leading commercial medical sites in intensive care units. This widespread rollout highlights the platform's deepening integration into routine clinical workflows, assisting medical teams to overcome cardiac imaging bottlenecks by delivering actionable data.
Recognizing its global impact, TIME magazine named UltraSight this week as one of the world's leading health-tech companies in its 'TIME World's Top HealthTech Companies 2026' ranking—marking further recognition of the company's innovation and growth on the global stage.
"We are entering the next phase of the company's growth at a time when our FDA-cleared product line continues to expand to support a broader range of cardiac imaging workflows," said Davidi Vortman, CEO and co-founder of UltraSight. "This funding will help accelerate market adoption, deepen strategic partnerships, and increase access to high-quality cardiac ultrasound—ultimately helping shorten the time to treatment for patients who simply cannot afford to wait."
Strategic Expansion and Board Strengthening
Dudi Klein, founder and managing partner at Alive, noted that UltraSight successfully combines solid clinical evidence with a scalable commercial model in a market defined by workforce shortages and access barriers. Prof. Rafi Beyar, former CEO of Rambam Health Care Campus and a partner at Alive, added that the technology possesses the potential to fundamentally transform how advanced imaging supports the diagnosis and treatment of structural heart diseases.
Alongside the funding round, UltraSight is strengthening its board of directors. Rick Geoffrion, recently appointed chairman of the board, brings over 30 years of experience in the cardiovascular medical device industry. Additional new board members include Dudi Klein, Tal Wandrov, managing partner at Star51 Capital, and Barak Ben-Eliezer, managing partner at Deep Insight.
